FERM domain-containing protein FRMD6 activates the mTOR signaling pathway and promotes lung cancer progression

FRMD6, a member of the 4.1 ezrin-radixin-moesin domain-containing protein family, has been reported to inhibit tumor progression in multiple cancers. Here, we demonstrate the involvement of FRMD6 in lung cancer progression. We find that FRMD6 is overexpressed in lung cancer tissues relative to in normal lung tissues. In addition, the enhanced expression of FRMD6 is associated with poor outcomes in patients with lung squamous cell carcinoma (n = 75, P = 0.0054) and lung adenocarcinoma (n = 94, P = 0.0330). Cell migration and proliferation in vitro and tumor formation in vivo are promoted by FRMD6 but are suppressed by the depletion of FRMD6. Mechanistically, FRMD6 interacts and colocalizes with mTOR and S6K, which are the key molecules of the mTOR signaling pathway. FRMD6 markedly enhances the interaction between mTOR and S6K, subsequently increasing the levels of endogenous pS6K and downstream pS6 in lung cancer cells. Furthermore, knocking out FRMD6 inhibits the activation of the mTOR signaling pathway in Frmd6(-/-) gene KO MEFs and mice. Altogether, our results show that FRMD6 contributes to lung cancer progression by activating the mTOR signaling pathway.

Automated summary

FRMD6, a member of the 4.1 ezrin-radixin-moesin domain-containing protein family, is overexpressed in lung cancer tissues and is associated with poor outcomes in patients with lung squamous cell carcinoma and lung adenocarcinoma. FRMD6 promotes cell migration, proliferation, and tumor formation in lung cancer by interacting with and enhancing the mTOR signaling pathway. Knocking out FRMD6 inhibits the activation of the mTOR signaling pathway in mouse models.